应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
SRPT Sarepta Therapeutics
已收盘 09-19 16:00:00 EDT
127.10
+2.09
+1.67%
盘后
127.10
+0.00
0.00%
18:50 EDT
最高
128.65
最低
125.61
成交量
63.69万
今开
126.41
昨收
125.01
日振幅
2.43%
总市值
121.21亿
流通市值
115.65亿
总股本
9,537万
成交额
8,119万
换手率
0.70%
流通股本
9,099万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Sarepta Therapeutics, Inc.2024财年第二财季实现净利润6.46百万美元,同比增加126.98%
自选股智能写手 · 08-17
Sarepta Therapeutics, Inc.2024财年第二财季实现净利润6.46百万美元,同比增加126.98%
Sarepta Therapeutics, Inc.盘中异动 快速下挫5.06%报132.97美元
自选股智能写手 · 08-08
Sarepta Therapeutics, Inc.盘中异动 快速下挫5.06%报132.97美元
BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX
Reuters · 08-07
BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX
BUZZ-莱林克认为礼来和 Sarepta 是动荡市场中的防御性股票
Reuters · 08-06
BUZZ-莱林克认为礼来和 Sarepta 是动荡市场中的防御性股票
Sarepta Therapeutics Inc 预计每股收益1美分 - 财报前瞻
Reuters · 08-06
Sarepta Therapeutics Inc 预计每股收益1美分 - 财报前瞻
Sarepta Therapeutics Inc 预计每股收益1美分 - 财报前瞻
Reuters · 07-29
Sarepta Therapeutics Inc 预计每股收益1美分 - 财报前瞻
Sarepta Therapeutics公司:RBC将其评级从“板块表现”上调至“跑赢大盘”
智通财经 · 07-29
Sarepta Therapeutics公司:RBC将其评级从“板块表现”上调至“跑赢大盘”
Piper Sandler:维持Sarepta Therapeutics(SRPT.US)评级,由增持调整至增持评级, 目标价由205.
智通财经 · 07-01
Piper Sandler:维持Sarepta Therapeutics(SRPT.US)评级,由增持调整至增持评级, 目标价由205.
Needham:重申Sarepta Therapeutics(SRPT.US)评级,由买入调整至买入评级, 目标价由235.
智通财经 · 06-27
Needham:重申Sarepta Therapeutics(SRPT.US)评级,由买入调整至买入评级, 目标价由235.
花旗:下调Sarepta Therapeutics(SRPT.US)评级,由买入调整至中性评级, 目标价由172.00美元调整至176.
智通财经 · 06-26
花旗:下调Sarepta Therapeutics(SRPT.US)评级,由买入调整至中性评级, 目标价由172.00美元调整至176.
Sarepta Therapeutics Inc:花旗集团将买入评级下调至中立
智通财经 · 06-26
Sarepta Therapeutics Inc:花旗集团将买入评级下调至中立
Leerink Partners:维持Sarepta Therapeutics(SRPT.US)评级,由优于大市调整至优于大市评级, 目标价由165.
智通财经 · 06-24
Leerink Partners:维持Sarepta Therapeutics(SRPT.US)评级,由优于大市调整至优于大市评级, 目标价由165.
Sarepta Therapeutics公司:BMO将目标价从170美元提高至200美元。
智通财经 · 06-24
Sarepta Therapeutics公司:BMO将目标价从170美元提高至200美元。
Sarepta Therapeutics公司:Leerink Partners将目标价从165美元上调至230美元。
智通财经 · 06-24
Sarepta Therapeutics公司:Leerink Partners将目标价从165美元上调至230美元。
美国研究综述-卡马斯、礼来、微策略
Reuters · 06-24
美国研究综述-卡马斯、礼来、微策略
Sarepta Therapeutics公司:摩根大通将目标价从175美元上调至205美元
智通财经 · 06-24
Sarepta Therapeutics公司:摩根大通将目标价从175美元上调至205美元
成分股Sarepta Therapeutics收涨30.14%,早盘一度涨超40%创最近六年最大盘中涨幅,美国食品药品管理局(FDA)一名高级官员推翻该机构评估人员的看法,大范围批准该公司针对儿童罕见肌肉疾病杜氏营养不良症(DMD)推出的Elevidys基因疗法。
华尔街见闻 · 06-22
成分股Sarepta Therapeutics收涨30.14%,早盘一度涨超40%创最近六年最大盘中涨幅,美国食品药品管理局(FDA)一名高级官员推翻该机构评估人员的看法,大范围批准该公司针对儿童罕见肌肉疾病杜氏营养不良症(DMD)推出的Elevidys基因疗法。
Piper Sandler:维持Sarepta Therapeutics(SRPT.US)评级,由增持调整至增持评级, 目标价由157.
智通财经 · 06-22
Piper Sandler:维持Sarepta Therapeutics(SRPT.US)评级,由增持调整至增持评级, 目标价由157.
Sarepta Therapeutics飙升40%,旗下基因疗法获扩大用途许可
老虎资讯综合 · 06-21
Sarepta Therapeutics飙升40%,旗下基因疗法获扩大用途许可
美股异动丨Sarepta Therapeutics飙升超40%,Elevidys获扩大用途许可Sarepta Therapeutics(SRPT.
格隆汇 · 06-21
美股异动丨Sarepta Therapeutics飙升超40%,Elevidys获扩大用途许可Sarepta Therapeutics(SRPT.
加载更多
公司概况
公司名称:
Sarepta Therapeutics
所属市场:
NASDAQ
上市日期:
--
主营业务:
Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司,专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术,并通过与战略合作伙伴的合作,该公司开发了多个获批产品,用于治疗杜氏肌营养不良症,并正在为广泛的疾病和紊乱开发潜在的候选治疗药物,包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。
发行价格:
--
{"stockData":{"symbol":"SRPT","market":"US","secType":"STK","nameCN":"Sarepta Therapeutics","latestPrice":127.1,"timestamp":1726776000000,"preClose":125.01,"halted":0,"volume":636891,"hourTrading":{"tag":"盘后","latestPrice":127.1,"preClose":127.1,"latestTime":"18:50 EDT","volume":65528,"amount":8328928.8,"timestamp":1726786229780},"delay":0,"floatShares":90992271,"shares":95366334,"eps":0.490812,"marketStatus":"已收盘","marketStatusCode":5,"change":2.09,"latestTime":"09-19 16:00:00 EDT","open":126.41,"high":128.65,"low":125.61,"amount":81187922.24358,"amplitude":0.024318,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.490812,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1726819200000},"adr":0,"listingDate":865396800000,"adjPreClose":125.01,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":126.75,"preClose":125.01,"latestTime":"09:11 EDT","volume":67,"amount":8534.240507999999,"timestamp":1726751519595},"postHourTrading":{"tag":"盘后","latestPrice":127.1,"preClose":127.1,"latestTime":"18:50 EDT","volume":65528,"amount":8328928.8,"timestamp":1726786229780},"volumeRatio":0.862276,"impliedVol":0.3981,"impliedVolPercentile":0.0992},"requestUrl":"/m/hq/s/SRPT","defaultTab":"news","newsList":[{"id":"2460242249","title":"Sarepta Therapeutics, Inc.2024财年第二财季实现净利润6.46百万美元,同比增加126.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460242249","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460242249?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:00","pubTimestamp":1723824028,"startTime":"0","endTime":"0","summary":"8月17日,Sarepta Therapeutics, Inc.公布财报,公告显示公司2024财年第二财季净利润为6.46百万美元,同比增加126.98%;其中营业收入为3.63亿美元,同比增加39.08%,每股基本收益为0.07美元。从资产负债表来看,Sarepta Therapeutics, Inc.总负债23.47亿美元,其中短期债务91.51百万美元,资产负债比为1.46,流动比率为3.91。机构评级:截至2024年8月17日,当前有18家机构对Sarepta Therapeutics, Inc.目标价做出预测,其中目标均价为195.83美元,其中最低目标价为148.00美元,最高目标价为220.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000419959f2b57&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240817000419959f2b57&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SRPT"],"gpt_icon":0},{"id":"2457314738","title":"Sarepta Therapeutics, Inc.盘中异动 快速下挫5.06%报132.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2457314738","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457314738?lang=zh_cn&edition=full","pubTime":"2024-08-08 21:57","pubTimestamp":1723125421,"startTime":"0","endTime":"0","summary":"北京时间2024年08月08日21时57分,Sarepta Therapeutics, Inc.股票出现异动,股价大幅跳水5.06%。截至发稿,该股报132.97美元/股,成交量63.2173万股,换手率0.66%,振幅2.91%。Sarepta Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为2.13%。Sarepta Therapeutics, Inc.公司简介:Sarepta Therapeutics公司是一家专注于治疗罕见、传染病和其他疾病的生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808215702aefdf111&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240808215702aefdf111&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IE00BJT1NW94.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4585","SRPT","LENZ","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2457732550","title":"BUZZ--美国股票走势-Lumen Technologies、Broadridge Financial、IDEXX","url":"https://stock-news.laohu8.com/highlight/detail?id=2457732550","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457732550?lang=zh_cn&edition=full","pubTime":"2024-08-07 00:30","pubTimestamp":1722961818,"startTime":"0","endTime":"0","summary":"美东时间12:14,道琼斯工业平均指数 上涨1.22%,报39,175.66点。标普500指数 上涨1.74%,报5276.66点;纳斯达克综合指数 上涨1.81%,报16492.856点。** CVS Health Corp :下跌 0.5%BUZZ - 巴克莱认为,成本上升趋势对 CVS 第二季度和全年利润构成风险 ** Jacobs Solutions Inc :上涨 1.2%BUZZ - 在第三季度收入超预期后上涨 ** IDEXX Laboratories Inc :上涨 4.3%BUZZ - 在预期下调并不像人们担心的那样糟糕之后,在缓解性反弹中上涨 标准普尔 500 指数的 11 个主要行业:通信服务","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","KVUE","TDG","GEHC","DDM","ZI","BUZZ",".SPX","BVS","PSQ",".IXIC","CAT","CVS","MCK","NQmain","UDOW","SRPT","CSX","MPC","FIS","MKTX","BR","DJX","HSIC","QID","TAP","HIMS","IDXX","EXPD","OGN","SQQQ","TALK","LUMN","BMRN","SPWR",".DJI","J","ELEV","VNO","ZTS","SDOW","BAX","TQQQ","DXD"],"gpt_icon":1},{"id":"2457704198","title":"BUZZ-莱林克认为礼来和 Sarepta 是动荡市场中的防御性股票","url":"https://stock-news.laohu8.com/highlight/detail?id=2457704198","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457704198?lang=zh_cn&edition=full","pubTime":"2024-08-06 20:36","pubTimestamp":1722947798,"startTime":"0","endTime":"0","summary":" 8月6日 - ** 经纪公司Leerink Partners称,礼来 和Sarepta Therapeutics 等股票有望在经济衰退的 \"动荡时期 \"跑赢大盘。** 默克 、Vaxcyte 和布鲁克 属于 \"现在值得重新审视 \"的股票,因为目前的抛售是买入这些股票的近期机会,这些股票最近因新闻流或股价表现困难而面临压力--Leerink** BMO Capital Markets称,SRPT、CRISPR Therapeutics 、Biomarin 和Legend Biotech 等公司因其强劲的产品收入而被 \"低估\",这些公司可在大幅下跌时提供保护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","BK4534","LU1066051225.USD","BMRN","BK4007","LU0965509283.SGD","LU0109391861.USD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU1023059063.AUD","LU0471298694.HKD","BK4548","IE00BJT1NW94.SGD","SGXZ23171101.USD","MCK","LLY","LU1093756168.USD","SRPT","PCVX","BRKR","LU1989771016.USD","BK4535","LU1037948897.HKD","BK4559","LU1280957306.USD","IE00BBT3K403.USD","IE00B19Z3B42.SGD","LU0256863811.USD","LU0208291251.USD","LU1814569148.SGD","IE00BJLML261.HKD","LU0251142724.SGD","IE0002270589.USD","BK4533","LU0058720904.USD","IE00BLSP4239.USD","BK4121","COR","LU1066051498.USD","BUZZ","LU1551013342.USD","TMO","LU0251131958.USD","IE00BKPKM429.USD","LU1066051811.HKD","LU2125909247.SGD","LU0211331839.USD","LU0868494617.USD","LEGN"],"gpt_icon":1},{"id":"2457058236","title":"Sarepta Therapeutics Inc 预计每股收益1美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457058236","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457058236?lang=zh_cn&edition=full","pubTime":"2024-08-06 10:08","pubTimestamp":1722910085,"startTime":"0","endTime":"0","summary":" * Sarepta Therapeutics Inc 将于8月7日公布截至0001年1月1日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,16位分析师的平均预期显示,这家总部位于马萨诸塞州剑桥市的公司预计将实现49.8%的营收增长,从去年同期的2.6124亿美元增至3.914亿美元。* LSEG 分析师对 Sarepta Therapeutics Inc 的平均预期为每股收益 1 美分。* 华尔街对 Sarepta Therapeutics Inc 的 12 个月目标价中位数为 200.00 美元,高于其上次收盘价 140.65 美元。8月6日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT","LENZ"],"gpt_icon":0},{"id":"2455198651","title":"Sarepta Therapeutics Inc 预计每股收益1美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455198651","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455198651?lang=zh_cn&edition=full","pubTime":"2024-07-29 20:05","pubTimestamp":1722254708,"startTime":"0","endTime":"0","summary":" * Sarepta Therapeutics Inc 预计将于7月31日公布截至2024年6月30日的季度业绩(预计),季度收入将有所增长。* LSEG 分析师对 Sarepta Therapeutics Inc 的平均预期为每股收益 1 美分。* 华尔街对 Sarepta Therapeutics Inc 的 12 个月目标价中位数为 200.00 美元,高于其上一交易日 144.24 美元的收盘价。7月29日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SRPT"],"gpt_icon":0},{"id":"2455311916","title":"Sarepta Therapeutics公司:RBC将其评级从“板块表现”上调至“跑赢大盘”","url":"https://stock-news.laohu8.com/highlight/detail?id=2455311916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455311916?lang=zh_cn&edition=full","pubTime":"2024-07-29 17:26","pubTimestamp":1722245197,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","SRPT","IE00B2B36J28.USD","BK4585","LENZ","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2448915990","title":"Piper Sandler:维持Sarepta Therapeutics(SRPT.US)评级,由增持调整至增持评级, 目标价由205.","url":"https://stock-news.laohu8.com/highlight/detail?id=2448915990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448915990?lang=zh_cn&edition=full","pubTime":"2024-07-01 21:53","pubTimestamp":1719842014,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","SRPT","IE0009355771.USD","BK4139","IE0002141913.USD","LENZ","BK4585","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2446197584","title":"Needham:重申Sarepta Therapeutics(SRPT.US)评级,由买入调整至买入评级, 目标价由235.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446197584","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446197584?lang=zh_cn&edition=full","pubTime":"2024-06-27 18:06","pubTimestamp":1719482788,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","BK4139","BK4585","SRPT","IE0002141913.USD","IE0009355771.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LENZ","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2446394185","title":"花旗:下调Sarepta Therapeutics(SRPT.US)评级,由买入调整至中性评级, 目标价由172.00美元调整至176.","url":"https://stock-news.laohu8.com/highlight/detail?id=2446394185","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446394185?lang=zh_cn&edition=full","pubTime":"2024-06-26 22:26","pubTimestamp":1719412017,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJT1NW94.SGD","LU0310800965.SGD","LU1267930227.SGD","BK4566","BK4207","BK4534","SRPT","LU0098860793.USD","LU0648001328.SGD","LU0980610538.SGD","BK4588","IE0002141913.USD","LU0320765646.SGD","LENZ","IE0009355771.USD","IE00B2B36J28.USD","BK4585","LU0052756011.USD","LU1201861249.SGD","LU1668664300.SGD","LU1162221912.USD","LU0128525689.USD","BK4504","LU0106831901.USD","IE00BFTCPJ56.SGD","BK4139","IE00BSNM7G36.USD","LU0130102774.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2446363252","title":"Sarepta Therapeutics Inc:花旗集团将买入评级下调至中立","url":"https://stock-news.laohu8.com/highlight/detail?id=2446363252","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2446363252?lang=zh_cn&edition=full","pubTime":"2024-06-26 18:35","pubTimestamp":1719398120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD","LU0320765646.SGD","BK4566","IE0009355771.USD","LU0106831901.USD","BK4585","BK4534","LU0980610538.SGD","IE00BJT1NW94.SGD","LU0052756011.USD","LU1267930227.SGD","IE00BJJMRZ35.SGD","BK4504","LU0310800965.SGD","SRPT","BK4588","LU1668664300.SGD","LENZ","LU1162221912.USD","LU1201861249.SGD","BK4207","LU0130102774.USD","LU0098860793.USD","LU0648001328.SGD","IE00BSNM7G36.USD","LU0128525689.USD"],"gpt_icon":0},{"id":"2445244027","title":"Leerink Partners:维持Sarepta Therapeutics(SRPT.US)评级,由优于大市调整至优于大市评级, 目标价由165.","url":"https://stock-news.laohu8.com/highlight/detail?id=2445244027","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445244027?lang=zh_cn&edition=full","pubTime":"2024-06-24 19:19","pubTimestamp":1719227969,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE0002141913.USD","IE00BJT1NW94.SGD","SRPT","IE0009355771.USD","BK4585","LENZ"],"gpt_icon":0},{"id":"2445024924","title":"Sarepta Therapeutics公司:BMO将目标价从170美元提高至200美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2445024924","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445024924?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:45","pubTimestamp":1719225906,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","SRPT","BMO","IE0002141913.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4207","LENZ","IE0009355771.USD","BK4139","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2445029906","title":"Sarepta Therapeutics公司:Leerink Partners将目标价从165美元上调至230美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2445029906","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445029906?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:10","pubTimestamp":1719223813,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","IE0009355771.USD","LENZ","IE00B2B36J28.USD","BK4585","IE00BJT1NW94.SGD","BK4139","SRPT","IE0002141913.USD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2445049041","title":"美国研究综述-卡马斯、礼来、微策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2445049041","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445049041?lang=zh_cn&edition=full","pubTime":"2024-06-24 15:45","pubTimestamp":1719215146,"startTime":"0","endTime":"0","summary":"要闻 * Carmax Inc :加拿大皇家银行将其目标价从 73 美元上调至 75 美元 * 礼来 :杰富瑞将目标价从994美元上调至1015美元 * 微策略公司 :Canaccord Genuity将目标价从2047美元下调至1826美元 * Sharecare Inc :Canaccord Genuity将目标价从买入下调至持有 * 赛默飞世尔科技公司 :加拿大皇家银行将目标价从662美元下调至660美元 以下是路透周一报导的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4587","BK4589","LU0251142724.SGD","LU0321505439.SGD","NVDA","SRPT","PAYC","IE00B1BXHZ80.USD","RGEN","GILD","SITC","BK4581","MPC","MSTR","TMUS","BK4579","DLR","CYRX","PYCR","LU1267930573.SGD","QDEL","WKHS","KMX","LNG","BK4578","IE00B3S45H60.SGD","LU1551013342.USD","PSX","COCH","T","LU0266512127.USD","TMO","IE00BJT1NW94.SGD","FDS","VZ","IFF","WAL","PCTY","BIO","LU1989771016.USD","LU0289739699.SGD","BK4588","VLO","CYTK","DAY","BK4585","LLY","SHCR","KBH"],"gpt_icon":0},{"id":"2445130700","title":"Sarepta Therapeutics公司:摩根大通将目标价从175美元上调至205美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445130700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445130700?lang=zh_cn&edition=full","pubTime":"2024-06-24 11:43","pubTimestamp":1719200623,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","SRPT","IE0009355771.USD","BK4139","IE0002141913.USD","LENZ","BK4585","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"2445972747","title":"成分股Sarepta Therapeutics收涨30.14%,早盘一度涨超40%创最近六年最大盘中涨幅,美国食品药品管理局(FDA)一名高级官员推翻该机构评估人员的看法,大范围批准该公司针对儿童罕见肌肉疾病杜氏营养不良症(DMD)推出的Elevidys基因疗法。","url":"https://stock-news.laohu8.com/highlight/detail?id=2445972747","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445972747?lang=zh_cn&edition=full","pubTime":"2024-06-22 05:05","pubTimestamp":1719003953,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["IE00B2B36J28.USD","BK4585","LU1951198990.SGD","IE0002141913.USD","LU1923623000.USD","PTC","BK4139","SRPT","LENZ","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","PACB","BK4588","BK4576","LU1951200564.SGD","BK4023","BK4554","IE00BFTCPJ56.SGD","BK4121","IE0009355771.USD"],"gpt_icon":0},{"id":"2445760962","title":"Piper Sandler:维持Sarepta Therapeutics(SRPT.US)评级,由增持调整至增持评级, 目标价由157.","url":"https://stock-news.laohu8.com/highlight/detail?id=2445760962","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445760962?lang=zh_cn&edition=full","pubTime":"2024-06-22 01:06","pubTimestamp":1718989587,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4585","BK4139","IE00B2B36J28.USD","LENZ","IE00BJT1NW94.SGD","SRPT","IE0009355771.USD"],"gpt_icon":0},{"id":"1151498625","title":"Sarepta Therapeutics飙升40%,旗下基因疗法获扩大用途许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1151498625","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151498625?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:45","pubTimestamp":1718981115,"startTime":"0","endTime":"0","summary":"公司宣布Elevidys获扩大用途许可,适用于4岁及以上的杜兴氏肌肉萎缩患者。","market":"us","thumbnail":"https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/bc7ad619aa7e42a7db4703997b65806b"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRPT"],"gpt_icon":0},{"id":"2445657997","title":"美股异动丨Sarepta Therapeutics飙升超40%,Elevidys获扩大用途许可Sarepta Therapeutics(SRPT.","url":"https://stock-news.laohu8.com/highlight/detail?id=2445657997","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2445657997?lang=zh_cn&edition=full","pubTime":"2024-06-21 22:41","pubTimestamp":1718980906,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0009355771.USD","IE00BJT1NW94.SGD","LENZ","SRPT","BK4139","IE0002141913.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","BK4585"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sarepta.com","stockEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0894},{"period":"3month","weight":0.0122},{"period":"6month","weight":-0.0198},{"period":"1year","weight":0.0495},{"period":"ytd","weight":0.2964}],"compareEarnings":[{"period":"1week","weight":0.0126},{"period":"1month","weight":0.0032},{"period":"3month","weight":0.0263},{"period":"6month","weight":0.0771},{"period":"1year","weight":0.2681},{"period":"ytd","weight":0.1811}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Sarepta Therapeutics, Inc.于1980年7月22日在俄勒冈州注册成立。该公司是一家商业阶段的生物制药公司,专注于通过发现和开发独特的RNA靶向疗法、基因疗法和其他用于治疗罕见疾病的基因治疗模式来帮助患者。应用他们的专有、高度差异化和创新技术,并通过与战略合作伙伴的合作,该公司开发了多个获批产品,用于治疗杜氏肌营养不良症,并正在为广泛的疾病和紊乱开发潜在的候选治疗药物,包括杜氏、肢带型肌营养不良症和其他与神经肌肉和中枢神经系统相关的疾病。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.050901},{"month":2,"riseRate":0.666667,"avgChangeRate":0.055118},{"month":3,"riseRate":0.5,"avgChangeRate":0.024789},{"month":4,"riseRate":0.333333,"avgChangeRate":0.013657},{"month":5,"riseRate":0.75,"avgChangeRate":0.176958},{"month":6,"riseRate":0.75,"avgChangeRate":0.09879},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.001448},{"month":8,"riseRate":0.692308,"avgChangeRate":0.083301},{"month":9,"riseRate":0.538462,"avgChangeRate":0.134461},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.101643},{"month":11,"riseRate":0.75,"avgChangeRate":0.091344},{"month":12,"riseRate":0.583333,"avgChangeRate":0.019375}],"exchange":"NASDAQ","name":"Sarepta Therapeutics","nameEN":"Sarepta Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.4","shortVersion":"4.26.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Sarepta Therapeutics,SRPT,Sarepta Therapeutics股票,Sarepta Therapeutics股票老虎,Sarepta Therapeutics股票老虎国际,Sarepta Therapeutics行情,Sarepta Therapeutics股票行情,Sarepta Therapeutics股价,Sarepta Therapeutics股市,Sarepta Therapeutics股票价格,Sarepta Therapeutics股票交易,Sarepta Therapeutics股票购买,Sarepta Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Sarepta Therapeutics(SRPT)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Sarepta Therapeutics(SRPT)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}